The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

At the American College of Cardiology (ACC) meeting this week, Merck showcased two components of its cardiovascular pipeline – sotatercept for pulmonary arterial hypertension (PAH) and oral ...

In the third quarter, Merck reported a decline of 11% in Gardasil sales to $2.31 billion. The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

The decision to terminate the HYPERION trial reflects a loss of clinical equipoise, making it unethical to continue the placebo-controlled study.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.